4.8 Article

Human Regulatory Dendritic Cells Develop From Monocytes in Response to Signals From Regulatory and Helper T Cells

Journal

FRONTIERS IN IMMUNOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.01982

Keywords

DCs; DCReg; Tregs; Th; monocytes

Categories

Funding

  1. NIH [HL075462, R01 CA222969, AI118884]

Ask authors/readers for more resources

Dendritic cells (DCs) are powerful antigen presenting cells, derived from bone marrow progenitors (cDCs) and monocytes (moDCs), that can shape the immune response by priming either proinflammatory or tolerogenic immune effector cells. The cellular mechanisms responsible for the generation of DCs that will prime a proinflammatory or tolerogenic response are poorly understood. Here we describe a novel mechanism by which tolerogenic DCs are formed from monocytes. When human monocytes were cultured with CD4(+)FoxP3(+)natural regulatory T cells (Tregs) and T helper cells (Th) from healthy donor blood, they differentiated into regulatory DCs (DCReg), capable of generating induced Tregs from naive T cells. DC(Reg)exhibited morphology, surface phenotype, cytokine secretion, and transcriptome that were distinct from other moDCs including those derived from monocytes cultured with Th or with GM-CSF/IL-4, as well as macrophages (M phi). Direct cell contact between monocytes, Tregs and Th, along with Treg-derived CTLA-4, IL-10 and TGF-beta, was required for the phenotypic differentiation of DCReg, although only IL-10 was required for imprinting the Treg-inducing capacity of DCReg. High ratios of Treg:Th, along with monocytes and DC(Reg)similar in function and phenotype to those inducedin vitro, were presentin situin human colorectal cancer specimens. Thus, through the combined actions of Tregs and Th, monocytes differentiate into DCs with regulatory properties, forming a positive feedback loop to reinforce Treg initiated immune regulation. This mechanism may contribute to immune tolerance in tissues such as tumors, which contain an abundance of Tregs, Th and monocytes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts

Omid Shah, John S. Tamaresis, Laura Jean Kenyon, Liwen Xu, Pingping Zheng, Puja Gupta, Krish Rangarajan, Stephanie Lee, Stephen Spellman, Sarah Nikiforow, James Zehnder, Everett H. Meyer

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Article Hematology

Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant

Pingping Zheng, John Tamaresis, Govindarajan Thangavelu, Liwen Xu, Xiaoqing You, Bruce R. Blazar, Robert S. Negrin, James L. Zehnder, Bettina P. Iliopoulou, Everett H. Meyer

BLOOD ADVANCES (2020)

Article Behavioral Sciences

Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia

Tyler R. Prestwood, Roshanak Asgariroozbehani, Sally Wu, Sri Mahavir Agarwal, Ryan W. Logan, Jacob S. Ballon, Margaret K. Hahn, Zachary Freyberg

Summary: Schizophrenia is characterized by inflammation and metabolic disturbances, with inflammation playing a key role in the disease. While antipsychotic drugs have revolutionized management of psychosis, they also lead to metabolic disturbances.

BEHAVIOURAL BRAIN RESEARCH (2021)

Article Immunology

Antibody Repertoire Analysis of Tumor-Infiltrating B Cells Reveals Distinct Signatures and Distributions Across Tissues

Ligal Aizik, Yael Dror, David Taussig, Adi Barzel, Yaron Carmi, Yariv Wine

Summary: The study found that B cells in the tumor microenvironment exhibit high clonal polarization and mutation rates, suggesting a local antigen-driven B-cell response. Importantly, these B cells are highly mutated but not class switched, indicating that class-switch recombination may be inhibited in the TME. Tracing the distribution of these B cell clones across compartments indicates their migration to and from the TME, suggesting that antibody repertoire signatures can be used as indicators for identifying tumor-reactive B cells.

FRONTIERS IN IMMUNOLOGY (2021)

Article Biochemistry & Molecular Biology

Lymph node colonization induces tumor-immune tolerance to promote distant metastasis

Nathan E. Reticker-Flynn, Weiruo Zhang, Julia A. Belk, Pamela A. Basto, Nichole K. Escalante, Genay O. W. Pilarowski, Alborz Bejnood, Maria M. Martins, Justin A. Kenkel, Ian L. Linde, Sreya Bagchi, Robert Yuan, Serena Chang, Matthew H. Spitzer, Yaron Carmi, Jiahan Cheng, Lorna L. Tolentino, Okmi Choi, Nancy Wu, Christina S. Kong, Andrew J. Gentles, John B. Sunwoo, Ansuman T. Satpathy, Sylvia K. Plevritis, Edgar G. Engleman

Summary: Lymph node metastasis plays an active role in shaping distant metastasis in solid malignancies, and this mechanism involves the evasion of immune cells, colonization in lymph nodes, and subsequent colonization in other tissues. This mechanism is conserved in human cancers and murine cancer models.
Editorial Material Immunology

Editorial: Implementing Logic Gates in Adoptive Cell Therapy

Gideon Gross, Yaron Carmi, Hinrich Abken

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B. Shnerb, Sooraj Mathukkada, Jebrane Bouaoud, Lucas Michon, Ofra Novoplansky, Mai Badarni, Limor Cohen, Ksenia M. Yegodayev, Sapir Tzadok, Barak Rotblat, Libor Brezina, Andreas Mock, Andy Karabajakian, Jerome Fayette, Idan Cohen, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Elena Voronov, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Luc G. T. Morris, Pierre Saintigny, Moshe Elkabets

Summary: In head and neck cancer, treatment with MEK1/2 inhibitor delays tumor progression and enhances antitumor immunity of CD8(+) T cells. Sensitizing tumors to immunotherapy during MEK1/2 inhibition can eliminate tumors and induce immune memory. Prolonged treatment with MEK1/2 inhibitor may lead to immunosuppressive tumor microenvironment due to epithelial to mesenchymal transition.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Biotechnology & Applied Microbiology

In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice

Alessio D. Nahmad, Cicera R. Lazzarotto, Natalie Zelikson, Talia Kustin, Mary Tenuta, Deli Huang, Inbal Reuveni, Daniel Nataf, Yuval Raviv, Miriam Horovitz-Fried, Iris Dotan, Yaron Carmi, Rina Rosin-Arbesfeld, David Nemazee, James E. Voss, Adi Stern, Shengdar Q. Tsai, Adi Barzel

Summary: In vivo engineering of B cells to secrete anti-HIV antibodies is a safe, potent, and scalable method that can be used for the treatment of infectious and noncommunicable diseases.

NATURE BIOTECHNOLOGY (2022)

Article Biology

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

Amit Gutwillig, Nadine Santana-Magal, Leen Farhat-Younis, Diana Rasoulouniriana, Asaf Madi, Chen Luxenburg, Jonathan Cohen, Krishnanand Padmanabhan, Noam Shomron, Guy Shapira, Annette Gleiberman, Roma Parikh, Carmit Levy, Meora Feinmesser, Dov Hershkovitz, Valentina Zemser-Werner, Oran Zlotnik, Sanne Kroon, Wolf-Dietrich Hardt, Reno Debets, Nathan Edward Reticker-Flynn, Peleg Rider, Yaron Carmi

Summary: Despite the successes of cancer immunotherapies, many patients experience partial response and relapse due to treatment resistance. This study reveals a previously unknown resistance mechanism where tumor cells form unique cell-in-cell structures to evade immunotherapy. Inhibiting specific factors involved in this process improves therapeutic efficacy.

ELIFE (2022)

Article Oncology

Neutrophil-activating therapy for the treatment of cancer

Ian L. Linde, Tyler R. Prestwood, Jingtao Qiu, Genay Pilarowski, Miles H. Linde, Xiangyue Zhang, Lei Shen, Nathan E. Reticker-Flynn, David Kung-Chun Chiu, Lauren Y. Sheu, Simon Van Deursen, Lorna L. Tolentino, Wen-Chao Song, Edgar G. Engleman

Summary: Although neutrophils are often used by cancers to promote immunosuppression, tumor growth, and metastasis, this study shows that neutrophils can be harnessed to induce eradication of tumors and reduce metastatic seeding. The combination of tumor necrosis factor, CD40 agonist, and tumor-binding antibody activates human neutrophils in vitro, leading to their lysis of human tumor cells. Mechanistically, this therapy mobilizes neutrophils to infiltrate tumors and activate complement, resulting in the production of leukotriene B4 and subsequent oxidative damage and T cell-independent clearance of multiple tumor types. These findings highlight the potential of using neutrophils as anti-tumor immune mediators.

CANCER CELL (2023)

Article Oncology

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

Shelley E. Ackerman, Cecelia I. Pearson, Joshua D. Gregorio, Joseph C. Gonzalez, Justin A. Kenkel, Felix J. Hartmann, Angela Luo, Po Y. Ho, Heidi LeBlanc, Lisa K. Blum, Samuel C. Kimmey, Andrew Luo, Murray L. Nguyen, Jason C. Paik, Lauren Y. Sheu, Benjamin Ackerman, Arthur Lee, Hai Li, Jennifer Melrose, Richard P. Laura, Vishnu C. Ramani, Karla A. Henning, David Y. Jackson, Brian S. Safina, Grant Yonehiro, Bruce H. Devens, Yaron Carmi, Steven J. Chapin, Sean C. Bendall, Marcin Kowanetz, David Dornan, Edgar G. Engleman, Michael N. Alonso

Summary: Alonso and colleagues have developed immune-stimulating antibody conjugates that can specifically deliver TLR7/8 agonists to tumors, inducing durable antitumor immunity.

NATURE CANCER (2021)

Article Oncology

Enteric Glia Play a Critical Role in Promoting the Development of Colorectal Cancer

Robert Yuan, Nupur Bhattacharya, Justin A. Kenkel, Jeanne Shen, Michael A. DiMaio, Sreya Bagchi, Tyler R. Prestwood, Aida Habtezion, Edgar G. Engleman

FRONTIERS IN ONCOLOGY (2020)

No Data Available